Relapsing Multiple Sclerosis (RMS) Clinical Trial
Official title:
A Multicenter, Prospective, Non-interventional Study to Assess Adherence to Treatment for patIeNts With RMS Who Are Prescribed Subcutaneous (sc) Interferon Beta-1a (MAIN-MS)
This is an open label, non randomized, uncontrolled, multicenter, single arm observational study. In this study, the enrolled subjects will be treated with Rebif human serum albumin (HSA)-free formulation (with or without RebiSmart) 44 microgram (mcg), subcutaneous (sc), thrice in a week (tiw) for 24 months.
n/a
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03277261 -
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS) ( ULTIMATE 1 )
|
Phase 3 | |
| Active, not recruiting |
NCT04130997 -
An Extension Study of Ublituximab in Participants With Relapsing Multiple Sclerosis
|
Phase 3 | |
| Terminated |
NCT04878211 -
A Open-label Study to Assess Response to COVID-19 Vaccine in Multiple Sclerosis Participants Treated With Ofatumumab
|
Phase 4 | |
| Recruiting |
NCT04086225 -
Effects of Cladribine Tablets on the Pharmacokinetics of Microgynon®
|
Phase 1 | |
| Completed |
NCT03745144 -
Effects of Cladribine Tablets on the PK of Microgynon®
|
Phase 1 | |
| Active, not recruiting |
NCT04667949 -
Study of Efficacy and Safety of Fingolimod (Gilenya) 0.5 mg in Chinese Patients With Relapsing Multiple Sclerosis (RMS) Patients
|
Phase 4 | |
| Completed |
NCT03277248 -
Study to Assess the Efficacy and Safety of Ublituximab in Participants With Relapsing Forms of Multiple Sclerosis (RMS)
|
Phase 3 |